Go to the list of all blogs
Joma Foster's Avatar
published in Blogs
Oct 28, 2026
TickeronGET DAILY SIGNALS
Quantum-Si (QSI) Analyst Targets Suggest +39% Upside, But the Path Is Far From Certain

Quantum-Si (QSI) Analyst Targets Suggest +39% Upside, But the Path Is Far From Certain

Key Takeaways

  • The $2.30 central target is the arithmetic mean of three verified analyst price targets reviewed for this article — H.C. Wainwright at $4.00, Alliance Global Partners at $1.90, and Canaccord Genuity at $1.00.
  • With Quantum-Si Incorporated (QSI) recently trading near $1.65, reaching $2.30 would require a gain of roughly 39%, a substantial move.
  • Individual targets span a very wide range, from $1.00 to $4.00, reflecting deep disagreement about the company's commercial outlook.
  • The bull case rests on the Proteus protein-sequencing platform and an extended cash runway; the bear case centers on a delayed launch, declining revenue, and Nasdaq listing compliance risk.
  • Ratings are split between two Buy ratings and one Hold, with no Sell ratings among the three analysts reviewed.
  • For more on this company, explore its Major News and Today's Price Move, along with its Forecast and Earnings pages.

Analyst Price Targets and Consensus View

Quantum-Si remains a thinly covered life-sciences name, and the limited number of published targets tells part of the story. I reviewed three current, attributable targets for this piece. H.C. Wainwright's Swayampakula Ramakanth reiterated a Buy rating with a $4.00 target in August 2026. Alliance Global Partners' Scott Henry kept a Buy rating but lowered his target to $1.90 from $2.50 after the second-quarter report. Canaccord Genuity reiterated a Hold rating with a $1.00 target in May 2026.

The arithmetic mean of these three figures comes to about $2.30, which serves as the rounded central target here. It is not an official consensus. The $1.00-to-$4.00 spread is unusually wide and signals that analysts are working from very different assumptions about whether Quantum-Si can turn its technology into commercial results. The two Buy-rated views focus on upside from the Proteus platform, while the Hold rating reflects caution around near-term commercialization and revenue.

Current Market Position and Path Toward the Target

Quantum-Si Incorporated (QSI) shares recently closed near $1.65 after a sharp rally that moved the stock well above its 52-week low of roughly $0.69. A move to $2.30 would imply upside of about 39%, which qualifies as substantial given the company's limited revenue and ongoing losses.

Progress toward that level would likely hinge on the Proteus platform, the company's next-generation single-molecule protein-sequencing technology. Management has outlined a controlled-to-commercial launch transition, yet the rollout has faced delays, pushing back the timeline for meaningful recurring revenue. Revenue stayed minimal at roughly $344,000 in the most recent quarter against a much larger cost base, so any sustained re-rating would need visible commercial milestones rather than valuation expansion alone. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What Could Support a Move Toward the Target

The main support comes from the Proteus platform and the broader proteomics opportunity. Quantum-Si is working to make protein sequencing more accessible and affordable, and successful demonstrations, including progress toward identifying all 20 standard amino acids, have sparked sharp rallies at times. Management has focused on cash conservation, including a workforce reduction, and has pointed to an extended runway into late 2028, which eases near-term financing concerns.

Analyst backing adds another layer. Two of the three tracked analysts maintain Buy ratings with targets well above the current price. If Proteus secures customer traction or if new partnerships or placements are announced, sentiment could shift quickly given the stock's high beta and news-driven trading patterns.

What Could Prevent the Target From Being Reached

The risks remain significant. Revenue has fallen sharply year over year, and the company continues to post deep losses on both a GAAP and operating basis. The delayed Proteus launch pushes back customer evaluations and consumables revenue, which means losses could continue for some time. Quantum-Si is not involved in quantum computing, and some of the recent share-price strength appears linked to investor confusion around that theme, which could reverse.

Nasdaq minimum bid-price compliance also poses a risk; failure to regain compliance could lead to delisting or actions such as a reverse stock split. Any future capital raise or secondary offering would likely weigh on the share price, and insider selling has been reported. Any of these factors could keep the stock well below $2.30.

Technical Levels and Market Structure

The stock's long-term range shows extreme volatility. Shares have moved from about $0.69 on the low end to the low $2.30s on the high end over the past year. The recent advance has brought the stock back toward the $2.00 psychological zone, with prior highs in the $2.32-to-$2.42 area serving as the next notable resistance. On the downside, the area near the last closing level around $1.46 and the $1.00 mark offer reference support zones. Given the high volatility, these levels should be treated as broad zones rather than exact turning points.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though the three firms do not publish identical timelines and one target predates the others. Investors should watch the next quarterly earnings report, expected in early November 2026, along with any updates on Proteus launch timing, customer placements, and consumables revenue. Cost discipline and cash-burn figures will matter, as will any news on Nasdaq compliance or future financing. Changes to analyst targets or ratings, especially from the two Buy-rated firms, would also serve as important signals.

Using AI Daily Buy/Sell Signals in My Research

Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile, event-driven name like Quantum-Si, these tools help surface opportunities, track positions, and identify changing trends more efficiently than manual chart review alone. Traders seeking a data-driven edge may find value in how these signals complement their own research process.

Final Assessment

The $2.30 figure represents a calculated average of three analyst targets, not a prediction of future performance. Reaching it would require a roughly 39% advance from around $1.65, a substantial move that depends largely on the Proteus platform achieving real commercial traction. The wide $1.00-to-$4.00 target range highlights genuine analyst disagreement on that outcome. Support comes from the platform's potential, an extended cash runway, and two Buy ratings; obstacles include the delayed launch, shrinking revenue, persistent losses, and listing-compliance risk. Investors should monitor Proteus milestones, the upcoming earnings report, and any analyst or financing developments before forming conclusions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: QSI

QSI's RSI Oscillator peaks and leaves overbought zone

The 10-day RSI Oscillator for QSI moved out of overbought territory on October 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 instances where the indicator moved out of the overbought zone. In 25 of the 26 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QSI as a result. In 83 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for QSI turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 37 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.

QSI moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for QSI crossed bearishly below the 50-day moving average on November 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where QSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

QSI broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 50-day moving average for QSI moved above the 200-day moving average on October 23, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +17.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where QSI advanced for three days, in 160 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

The Aroon Indicator entered an Uptrend today. In 94 of 122 cases where QSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. QSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.616) is normal, around the industry mean (4.142). P/E Ratio (-2.891) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (100.000) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry MedicalNursingServices

Industry
N/A
Address
29 Business Park Drive
Phone
+1 866 688-7374
Employees
138
Web
https://www.quantum-si.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.